NCT00359190 - Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 29, 2004

Primary Completion Date

January 9, 2008

Study Completion Date

January 9, 2008

Conditions

Neoplasms, Breast

Interventions

DRUG

lapatinib

GW572016 ditosylate salt (lapatinib) will be given as 250 mg tablets via oral route

Trial Locations (10)

GSK Investigational Site, Pittsburgh

GSK Investigational Site, Allentown

GSK Investigational Site, Roanoke

GSK Investigational Site, Durham

GSK Investigational Site, Nashville

GSK Investigational Site, Ramat Gan

GSK Investigational Site, Milwaukee

GSK Investigational Site, Zrifin

GSK Investigational Site, Dallas

GSK Investigational Site, Miami